On 8 October 2025, CF PharmTech, Inc. (2652.HK, CF PharmTech) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 608 million. CBI is honored to participate in the due diligence work for this IPO Project.

CF PharmTech is a company primarily focused on the research & development, manufacturing and commercialization of inhalation technologies and inhalation drugs. The Company’s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, suppliers, customers and distributors. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting reputation intelligence and related company search. The due diligence project globally covered 6 countries and regions, including China, Hong Kong, the United States, the United Kingdom and Switzerland, etc.